. Several aspects of the alterations in body function associated with administration of reserpine to man have been reported: in two schizophrenics who had received reserpine, de la Lande and associates (6) showed that ephedrine infused into the brachial artery had no effect on forearm blood flow; Westfall and Watts (7) showed that in normal students there was a diminished response of blood pressure and finger temperature to smoking after fourteen days of reserpine administration; Burger (8) found diminished plasma norepinephrine levels, and Gaddum, Krivoy, and Laverty (9) and Carlsson, Rasmussen, and Kristjansen (10) described decreased urinary excretion of catecholamines after long term reserpine administration. However, there appear to be no formal studies in man showing that reserpine affects cardiovascular responses, as has been postulated to explain the circulatory collapse which may occur in patients who have received reserpine and are subjected to anesthesia ( 11 ) and shock therapy (12) . Depletion of the tissue stores of norepin'ephrine should result in a reduced pressor effect of tyramine, as this is believed to be due entirely to release of endogenous norepinephrine (13) (14) . 
MATERIAL AND METHODS
Twelve male patients aged 37 to 73 were studied (Table  I ). They had all been in-patients for a considerable time and were free of obvious cardiovascular disease, ascites, and peripheral neuropathy. They were not receiving reserpine, sympathomimetic amines, or monamine oxidase inhibitors.
The subject lay comfortably on a couch, and polyethylene catheters were placed in the brachial artery on one side and a forearm vein on the other. Blood pressure was recorded continuously with a Sanborn capacitance manometer model no. 267B or a Statham resistance manometer model no. 23B4 and a Sanborn recorder model no. 150M. In some studies, the blood pressure was electrically meaned, in others an instantaneous recording was obtained and mean arterial pressure (MAP) estimated by the formula MAP = diastolic blood pressure plus % pulse pressure. Cardiac outputs (CO) were estimated by dye dilution with indocyanine green, a Colson cuvette densitometer model no. 110 I.R., and Harvard pump model 600-900. Duplicate determinations of CO before injections of tyramine gave 95% confidence limits for the method of + 0.64 L per mm. Total peripheral resistance (TPR) was calculated from the formula TPR (dyne-seccm') =80 X MAP (mm Hg)/CO (L per minute).
Each subject was studied on two occasions 48 hours apart. On day 1, after the catheters were satisfactorily Laennec's cirrhosis R 2 
73
No organic disease R 3 54 Convalescent from diarrhoea R 4 37
Korsakoff's psychosis R 5 60 Carcinoma of larynx R 6 51
Multiple sclerosis C, R* 7 43
Healed duodenal ulcer C 8 69 Cerebral thrombosis C The responses of all 12 subjects to the first injection of tyramine are listed in Table II .
Pulse rate. Data on pulse rate after tyramine are available in nine subjects. In four there was a rise of 16 to 27 beats per minute (average, 22 beats per minute) which reached a peak in 1 to 2 minutes; in one of these subjects there was a subsequent fall. In five subjects there was a fall in pulse rate of 12 to 27 beats per minute (average, 21 beats per minute) reaching a nadir at 3 minutes. Pulse rate had usually returned to preinjection level within 5 minutes.
Blood pressure. MAP rose in all subjects owing to a rise in both systolic and diastolic pressures, the absolute increase in the former being about three times the latter. Peak increment of MAP averaged 45.7 mm Hg and occurred at from 1 to 4 minutes after injection (average, 2 minutes). 10 mm Hg below the preinjection level. The
The pressor effect was short-lived, and the MAP MAP has also been graphed against time and the had returned to preinjection levels within 5 to 10 area included between this curve and the preinminutes (average 5.7 minutes). There was fre-jection level measured, (Figure 2 ) to provide an quently a subsequent period when MAP was 5 to estimate of drug effect which takes account of of the 12 subjects; the changes were not consistent in direction. In 5 of the 11 subjects, the change exceeded the 95% confidence limits, and of these, two were increases and three decreases.
Total peripheral resistance. At 1½ minutes after the injection, the calculated TPR was greater than the preinjection level in 9 of the 11 subjects. The remaining two were unchanged. The mean increase for the whole group was 876 dyne-seccm-5. Five minutes after the injection, there was no significant difference from the preinjection level.
II. Effects of reserpine on resting values.
Eight subjects received reserpine. Three of them complained of a "washed-out feeling," the other five appeared untroubled by the drug. Data used in these comparisons together with data from the five untreated controls are listed in Table  IV. Pulse rate. Resting pulse rate fell by an average of 13 Valsalva maneuver. Seven subjects performed a Valsalva maneuver before and after reserpine. Before reserpine, the overshoot usually seen at the conclusion of apnea was observed in only two subjects; in both of these, as well as the other five, it was not seen after reserpine.
III. Effects of reserpine on the response to tyramine A comparison was made between the tyramine responses before and after reserpine by using a paired t test. To exclude systematic error unrelated to reserpine administration, the result was contrasted with that of a similar comparison in the control subjects. The data are presented in Table V .
Pulse rate. No consistent modification of pulse rate response to tyramine appeared to follow reserpine, but the changes were smaller.
Blood pressure. Reserpine did not change the form of the pressor response to tyramine, but reduced its magnitude. (Figure 3 ).
In contrast, in paired observations on the five control subjects, the average peak MAP rise on day 1 was 43.0 mm Hg and on day 3, 41.8 mm Hg. The difference of -1.2 mm Hg was not significant. The mean area on day 1 was 127.6 mmminutes and on day 3, 132.4 mm-minutes; the difference was + 4.8 mm-minutes and was not significant.
Cardiac output. The changes in CO produced by tyramine in the reserpine-treated subjects were as variable as before reserpine.
Total peripheral resistance. After reserpine the rise in calculated TPR produced by tyramine was less than before reserpine in all six subjects. The reduction in response was significant at the 1%7o level.
DISCUSSION
Interest in tyramine dates from the early period of the study of sympathomimetic amines (15) . Although the pharmacological action and structure of tyramine resemble that of norepinephrine, important differences in its actions can be demonstrated. Denervation of the cat nictitating membrane results in supersensitivity to injected norepinephrine but subsensitivity to injected tyramine (16) . Also, animals depleted of catecholamines by reserpine pretreatment are no longer sensitive to tyramine, but remain responsive to epinephrine (13) . These observations led Burn and Rand (13) to hypothesize that tyramine acted indirectly by releasing endogenous tissue catecholamine. Subsequently it has been shown (17) that the cat nictitating membrane pretreated with reserpine was subsensitive to tyramine and that this was related to depletion of norepinephrine stores. Thus, the available evidence is compatible with the suggestion that tyramine exerts its sympat'Lomimetic effects by liberating norepinephrine from peripheral stores.
It has been further hypothesized (18) (19) that catecholamine stores are contained in two compartments, a smaller store of "available" norepinephrine liberated by tyramine and a larger store of bound catecholamines which is depleted by reserpine. In guinea pig atria (19) it has been demonstrated that 50%o depletion of catecholamines by reserpine produced a slightly reduced response to tyramine, but a 50%o reduction of the tyramine response occurred with decrease of the normal noradrenaline content to 10%o. Such observations have not been made for tissues other than cardiac tissue. Although the observations of Gaffney, Morrow, and Chidsey (20) suggest that most of the cardiac effects of tyramine result from release of myocardial catecholamines, the exact role played by release of catecholamines from different tissues in the total biological response to tyramine remains to be worked out. It is unlikely that such direct evidence will be available in man, although the work of Crout, Muskus, and Trendelenburg (19) might suggest that the doses of reserpine used in this study have resulted in depletion of more than 50% of the norepinephrine store.
Although tyramine was used for a time as a morphine antagonist in obstetric practice (21) , it now finds no place in therapeutics. Apart from the studies reported by Hewlett (22) and Meyer and Eckers (23) , there appear to have been no data available on its effect in man until recently (24, 25) . Tyramine is unlikely to replace presently used pressor agents in treatment, but the response to tyramine does provide a measure of the functional integrity of tissue catecholamine stores. Thus in the reserpine-treated spinal cat preparation studied by Trendelenburg (18) , the responses of the nictitating membrane to sympathetic nerve stimulation and to tyramine administration showed parallel impairment over a wide range of responsiveness. It is not established that such a precise relationship holds in the intact man with the blood pressure response as the observed statistic. Nevertheless, this work has shown that the pressor response to tyramine has proved reproducible. Crandell (26) has recommended the injection of 15 mg ephedrine prior to surgery to test the availability of endogenous catecholamines and the vascular reactivity to them, but does not give details to support its validity. Furthermore, in the dog heart-lung preparation (27) and in the spinal cat preparation (28) , ephedrine has been shown to have a direct action in addition to the indirect component which is abolished by reserpine. Tyramine is preferable to other indirectly acting amines such as amphetamine and metamphetamine, since its transitory action can be observed in full over the course of 5 to 10 minutes. Further study of the response to tyramine in clinical situations is necessary to establish its usefulness as such a test.
The data on the effect of reserpine on the resting state are not very striking. The cause of the fall in resting MAP is not obvious from the present studies. Reduction in the force of myocardial contraction after reserpine might be predicted from Sarnoff's (29) demonstration of the importance of catecholamines in maintaining cardiac function. However, decrease in CO in these subjects was not statistically significant, although the precision of the estimation is sufficient to detect only gross changes. Larger doses of reserpine than the moderate amounts given here, or more prolonged administration, might produce unequivocal reduction in CO. These data provide no evidence that vasodilatation and consequent lowering of TPR due to reserpine are the factors responsible for the hypotensive effect. De la Lande and associates have shown that vasodilatation (6) follows '/2 to 1 hour after infusion of reserpine into the brachial artery and lasts for at least 24 hours. This vasodilatation may perhaps be responsible for the prompt hypotensive response to parenteral reserpine, which follows a similar time course, but in view of the above conclusion, it is probably not the explanation of the observations in this study.
The blood pressure response to tyramine is comparatively reproducible from day to day. In contrast, the second response to tyramine in the reserpine-treated subjects was markedly less than the first in all eight patients.
The reduction of the response to tyramine which has been demonstrated is probably due to depletion of tissue stores of norepinephrine. However, inability to release norepinephrine due to reserpine or densitization of the end organ must be considered possible. The latter is unlikely in view of the abundant animal work (30) demonstrating normal sensitivity or supersensitivity of various reserpine-treated preparations to norepinephrine as well as observations on the effectiveness of norepinephrine in reducing human forearm blood flow in reserpine-treated patients (6) . The possibility that reserpine blocks the release of norepinephrine by tyramine is nowhere suggested in the work on animals and is unlikely, since at the end of 24 hours little if any reserpine would still be present in the body (31) . However, it is not excluded by the present study.
SUMMARY
In eight subjects, pretreatment with reserpine, 0.06 mg per kg, produced a significant reduction in the blood pressure response to tyramine, 0.2 mg per kg, which was not observed in five control subjects. Similarly, the rise of total peripheral resistance produced by tyramine was reduced significantly by reserpine. Resting cardiac output was not altered by this dose of reserpine, but resting mean blood pressure was lowered significantly.
These observations in man are consistent with the hypothesis that tyramine acts by release of endogenous norepinephrine and that therapeutic doses of reserpine produce a reduced response to tyramine, probably by reducing endogenous catecholamine stores.
